COVID-19: PHARMACOLOGICAL AND THERAPEUTIC APPROACHES
In the end of 2019, SARS-CoV-2, a new virus from Corona viruses family, has been detected in China and was responsible for COVID-19 disease. This disease has been suddenly and vigorously disseminated among individuals all over the world. Based on genetic vicinity, this novel virus is similar to SARS-CoV and MERS-CoV and it can spread from an unknown animal host to individuals. Many published clinical data and in vitro studies may offer treatment strategies of some effective antiviral and repurposed drugs, including remdesivir, favipiravir, lopinavir/ritonavir, corticosteroids, etc. This narrative review describes current pharmacological proposed treatments for COVID-19 patients and available experimental and clinical studies for these drugs. Eventually, these data may help to explain the most preferable way to treat COVID-19 and lessen the accompanied symptoms and complications.
Peer Review History:
Received 6 November 2020; Revised 25 December; Accepted 4 January, Available online 15 January 2021
UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main purpose of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency.
Average Peer review marks at initial stage: 5.5/10
Average Peer review marks at publication stage: 7.5/10